These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 9278190)

  • 21. [Interaction of neurotransmitters in specific circuits of the brain].
    Mora Teruel F
    An R Acad Nac Med (Madr); 1998; 115(3):653-7; discussion 657-8. PubMed ID: 10208018
    [No Abstract]   [Full Text] [Related]  

  • 22. The neuropathology of schizophrenia.
    Bachus SE; Kleinman JE
    J Clin Psychiatry; 1996; 57 Suppl 11():72-83. PubMed ID: 8941174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cortical microcircuits in schizophrenia--the dopamine hypothesis revisited.
    Winterer G
    Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S68-71. PubMed ID: 16508900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anatomical substrates for glutamate-dopamine interactions: evidence for specificity of connections and extrasynaptic actions.
    Sesack SR; Carr DB; Omelchenko N; Pinto A
    Ann N Y Acad Sci; 2003 Nov; 1003():36-52. PubMed ID: 14684434
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hippocampal neurons in schizophrenia.
    Heckers S; Konradi C
    J Neural Transm (Vienna); 2002 May; 109(5-6):891-905. PubMed ID: 12111476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decreased expression of vesicular glutamate transporter 1 and complexin II mRNAs in schizophrenia: further evidence for a synaptic pathology affecting glutamate neurons.
    Eastwood SL; Harrison PJ
    Schizophr Res; 2005 Mar; 73(2-3):159-72. PubMed ID: 15653259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biological factors in schizophrenia. Structural and functional aspects.
    Syvälahti EK
    Br J Psychiatry Suppl; 1994 Apr; (23):9-14. PubMed ID: 7913612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cortical dopamine in schizophrenia: strategies for postmortem studies.
    Lewis DA; Akil M
    J Psychiatr Res; 1997; 31(2):175-95. PubMed ID: 9278185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Glutamatergic neurotransmission in schizophrenics].
    Bleich S; Bleich K; Wiltfang J; Maler JM; Kornhuber J
    Fortschr Neurol Psychiatr; 2001 Sep; 69 Suppl 2():S56-61. PubMed ID: 11533851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 5-HT
    Huang M; Kwon S; Rajagopal L; He W; Meltzer HY
    Psychopharmacology (Berl); 2018 Oct; 235(10):2795-2808. PubMed ID: 30066135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frontal Glutamate and γ-Aminobutyric Acid Levels and Their Associations With Mismatch Negativity and Digit Sequencing Task Performance in Schizophrenia.
    Rowland LM; Summerfelt A; Wijtenburg SA; Du X; Chiappelli JJ; Krishna N; West J; Muellerklein F; Kochunov P; Hong LE
    JAMA Psychiatry; 2016 Feb; 73(2):166-74. PubMed ID: 26720179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The biological basis of schizophrenia: new directions.
    Weinberger DR
    J Clin Psychiatry; 1997; 58 Suppl 10():22-7. PubMed ID: 9265913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of glutamate and gamma-aminobutyric acid uptake binding sites in frontal and temporal lobes in schizophrenia.
    Simpson MD; Slater P; Deakin JF
    Biol Psychiatry; 1998 Sep; 44(6):423-7. PubMed ID: 9777172
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of the glutamate, GABA, and dopamine systems in relation to NRH-induced neurotoxicity.
    Benes FM
    Biol Psychiatry; 1995 Dec; 38(12):783-7. PubMed ID: 8750035
    [No Abstract]   [Full Text] [Related]  

  • 35. Multiple inputs of GABA-immunoreactive neurons in the cuneate nucleus of the rat.
    Lue JH; Jiang-Shieh YF; Shieh JY; Ling EA; Wen CY
    Neurosci Res; 1997 Feb; 27(2):123-32. PubMed ID: 9100254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.
    Pietraszek M
    Pol J Pharmacol; 2003; 55(2):133-54. PubMed ID: 12926541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
    Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
    Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced GABA uptake sites in the temporal lobe in schizophrenia.
    Simpson MD; Slater P; Deakin JF; Royston MC; Skan WJ
    Neurosci Lett; 1989 Dec; 107(1-3):211-5. PubMed ID: 2616032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interactions of dopamine with glutamate- and GABA-mediated synaptic transmission in the rat entorhinal cortex in vitro.
    Pralong E; Jones RS
    Eur J Neurosci; 1993 Jun; 5(6):760-7. PubMed ID: 7903191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regionally selective deficits in uptake sites for glutamate and gamma-aminobutyric acid in the basal ganglia in schizophrenia.
    Simpson MD; Slater P; Royston MC; Deakin JF
    Psychiatry Res; 1992 Jun; 42(3):273-82. PubMed ID: 1353892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.